Source-grounded facts extracted from EyePoint, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
EyePoint, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm Deloitte & Touche LLP at the 2026-04-21 meeting.
“Proposal No. 4. Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting on this proposal is set forth below:”
EyePoint, Inc. shareholders approved Non-Binding Advisory Vote on Named Executive Officer Compensation at the 2026-04-21 meeting.
“Proposal No. 3. Non-Binding Advisory Vote on Named Executive Officer Compensation The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The voting on this proposal is set forth below:”
EyePoint, Inc. shareholders approved Amendment to 2023 Long-Term Incentive Plan to increase the number of shares of Common Stock authorized for issuance thereunder by 4,900,000 shares at the 2026-04-21 meeting.
“Proposal No. 2. Amendment to 2023 Long-Term Incentive Plan The Company’s stockholders approved the 2023 Plan Amendment to increase the number of shares of Common Stock authorized for issuance thereunder by 4,900,000 shares. The voting on this proposal is set forth below:”
EyePoint, Inc. shareholders approved Election of Directors at the 2026-04-21 meeting.
“Proposal No. 1. Election of Directors The Company’s stockholders elected the following directors to the Board, each to serve until the Company’s 2027 Annual Meeting of Stockholders and until such person’s successor is duly elected and qualified. The voting on this proposal is set forth below:”
EyePoint, Inc. reported first quarter ended March 31, 2026 results: revenue $0.7 million, net income net loss was $84.8 million, EPS ($0.99) per share.
“or DURAVYU-related ocular or systemic SAEs. Review of Results for the First Quarter Ended March 31, 2026 For the first quarter ended March 31, 2026, total net revenue was $0.7 million compared to $24.5 million for the corresponding period in 2025. The decrease was primarily driven by the recognition of remaining deferred revenue related to the Company’s 2023”
EyePoint, Inc. reported the fourth quarter and full-year ended December 31, 2025 results: revenue $0.6 million.
“million in October 2025. Exhibit 99.1 Review of Results for the Fourth Quarter Ended December 31, 2025 For the fourth quarter ended December 31, 2025, total net revenue was $0.6 million compared to $11.6 million for the quarter ended December 31, 2024. Net product revenue for the fourth quarter was $0.3 million, compared to net product revenue for the”
EyePoint, Inc.: On December 8, 2025, the Company filed a certificate of amendment to its Certificate of Incorporation to change its name from 'EyePoint Pharmaceuticals, Inc.' to 'EyePoint, Inc.', effective December 8, 2025 (effective 2025-12-08).
“On December 8, 2025, EyePoint, Inc. (the “Company”) filed a certificate of amendment (the “Certificate of Amendment”) to its Certificate of Incorporation, as amended, solely to change the Company’s name from “EyePoint Pharmaceuticals, Inc.” to “EyePoint, Inc.” The name change became effective on December 8, 2025.”
Dr. Reginald Sanders was appointed as Director at EyePoint, Inc..
“appointed Dr. Reginald Sanders, M.D. to fill the vacancy on the Board, effective January 8, 2025.”
Fred Hassan was appointed as Director at EyePoint, Inc..
“the Board, upon the recommendation of the Governance and Nominating Committee of the Board (the "Governance and Nominating Committee"), reduced the size of the Board from nine to eight members and appointed Fred Hassan to fill the remaining vacancy on the Board.”
Anthony P. Adamis resigned as Director at EyePoint, Inc..
“On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.”
David R. Guyer resigned as Director at EyePoint, Inc..
“On September 3, 2024, David R. Guyer, M.D. and Anthony P. Adamis, M.D. resigned from the Board of Directors (the "Board") of EyePoint Pharmaceuticals, Inc. (the "Company") and all committees thereof, effective immediately.”
EyePoint, Inc. reported the first quarter ended March 31, 2024 results: revenue $11.7 million, net income $29.3 million, EPS ($0.55) per share.
“For the first quarter ended March 31, 2024, total net revenue was $11.7 million compared to $7.7 million for the quarter ended March 31, 2023. Net product revenue for the first quarter was $0.7 million, compared to net product revenues for the first quarter ended March 31, 2023 of $7.4 million. This decrease in net product revenue resulted from the out-license of the YUTIQ franchise in May 2023, completing the strategic pivot from a commercial company to a biopharmaceutical pipeline-focused company. Net revenue from royalties and collaborations for the first quarter ended March 31, 2024 totaled $11.0 million compared to $0.3 million in the corresponding period in 2023. This increase was primarily due to partial recognition of deferred revenue from the license of the YUTIQ franchise, which begun in 2Q 2023 and will be recognized over a 2-year period in connection with the delivery of YUTIQ supply units. Operating expenses for the first quarter ended March 31, 2024 totaled $45.0 million”
EyePoint, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On March 7, 2024, EyePoint Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023 and certain other information.”
EyePoint, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC, as representative of the underwriters named therein valued at approximately $215.9 million (effective 2023-12-05).
“On December 5, 2023, EyePoint Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten public offering (the “Offering”) of 11,764,706 shares of the Company’s common stock”
EyePoint, Inc. reported the third quarter ended September 30, 2023 results: revenue $15.2 million, net income $(12.6) million, EPS ($0.33) per share.
“For the third quarter ended September 30, 2023, total net revenue was $15.2 million compared to $10.0 million for the quarter ended September 30, 2022.”
Stuart Duty was appointed as Director at EyePoint, Inc..
“increased the size of the Board to ten (10) members and appointed Stuart Duty to fill the vacancy on the Board, effective October 16, 2023.”
EyePoint, Inc. reported second quarter ended June 30, 2023 results: revenue total net revenue was $9.1 million.
“For the second quarter ended June 30, 2023, total net revenue was $9.1 million compared to $11.6 million for the quarter ended June 30, 2022.”
Jay S. Duker was appointed as Director at EyePoint, Inc..
“appointed Dr. Duker to fill the vacancy for the newly created directorship”
Jay S. Duker was appointed as President and Chief Executive Officer at EyePoint, Inc..
“the Company appointed Dr. Duker as the Company's President and Chief Executive Officer, effective as of July 10, 2023”
Nancy S. Lurker changed role as Executive Vice Chair at EyePoint, Inc..
“Nancy S. Lurker transitioned from her role as Chief Executive Officer of EyePoint Pharmaceuticals, Inc. (the “Company”) to Executive Vice Chair of the Company.”
EyePoint, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2023-12-31 meeting.
“Proposal No. 4. Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The voting on this proposal is set forth below: Vote Type Vote Results For 29,572,517 Against 138,031 Abstain 4,909 Non Votes 0”
EyePoint, Inc. shareholders approved Non-Binding Advisory Vote on Named Executive Officer Compensation.
“Proposal No. 3. Non-Binding Advisory Vote on Named Executive Officer Compensation The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The voting on this proposal is set forth below: Vote Type Vote Results For 25,419,375 Against 206,043 Abstain 80,803 Non Votes 4,009,236”
EyePoint, Inc. shareholders approved 2023 Long-Term Incentive Plan.
“Proposal No. 2. 2023 Long-Term Incentive Plan The Company’s stockholders approved the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan. The voting on this proposal is set forth below: Vote Type Vote Results For 21,899,109 Against 3,738,891 Abstain 68,221 Non Votes 4,009,236”
EyePoint, Inc. shareholders approved Election of Directors.
“Proposal No. 1. Election of Directors The Company’s stockholders elected the following directors to the Board, each to serve until the Company’s 2024 Annual Meeting of Stockholders or until such person’s successor is duly elected and qualified. The voting on this proposal is set forth below: Vote Type Vote Results Göran Ando, M.D. For 25,523,018 Withheld 183,203 Broker Non-Votes 4,009,236 Nancy S. Lurker For 25,578,006 Withheld 128,215 Broker Non-Votes 4,009,236 John B. Landis, Ph.D. For 25,578,624 Withheld 127,597 Broker Non-Votes 4,009,236 David R. Guyer, M.D. For 25,562,931 Withheld 143,290 Broker Non-Votes 4,009,236 Wendy F. DiCicco For 25,570,654 Withheld 135,567 Broker Non-Votes 4,009,236 Ye Liu For 25,576,789 Withheld 129,432 Broker Non-Votes 4,009,236 Anthony P. Adamis For 25,568,829 Withheld 137,392 Broker Non-Votes 4,009,236 Karen Zaderej For 25,632,878 Withheld 73,343 Broker Non-Votes 4,009,236”
EyePoint, Inc. announced a restructuring with charges of approximately $1.2 million to $1.6 million in total pre-tax charges affecting sales and marketing organization and other supporting roles (approximately 35 employees).
“of a separation agreement, which includes a general release of claims against the Company. The Company estimates that the implementation of the RIF will result in approximately $1.2 million to $1.6 million in total pre-tax charges and cash outlays for termination of employees. The Company expects the charges will be incurred primarily in the second quarter of 2023,”
EyePoint, Inc. completed a disposition involving Alimera Sciences, Inc. for Upfront payment of $75 million, four quarterly guaranteed payments totaling $7.5 million during 2024, and royalties from 2025 to 2028 at a percentage of low-to- (closed 2023-05-17).
“(the “ Company ”) entered into a product rights agreement (the “ Product Rights Agreement ”) with Alimera Sciences, Inc. (“ Alimera ”) to grant to Alimera an exclusive (even as to the Company) and sublicensable (in accordance with the terms of the Product Rights Agreement) right and license (the “ License ”) under the Company’s and its affiliates’ interest in certain of the Company’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment and prevention of uveitis in the entire world except Europe, the Middle East and Africa (the “ Licensed Territory ”).”
EyePoint, Inc. entered into Product Rights Agreement with Alimera Sciences, Inc. valued at $75 million (effective 2023-05-17).
“On May 17, 2023 (the " Closing Date "), EyePoint Pharmaceuticals, Inc. (the " Company ") entered into a product rights agreement (the " Product Rights Agreement ") with Alimera Sciences, Inc. (" Alimera ") to grant to Alimera an exclusive (even as to the Company) and sublicensable (in accordance with the terms of the Product Rights Agreement) right and license (the " License ") under the Company’s and its affiliates’ interest in certain of the Company’s and its affiliates’ intellectual property to develop, manufacture, sell, commercialize and otherwise exploit certain products, including YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment and prevention of uveitis in the entire world except Europe, the Middle East and Africa (the " Licensed Territory ").”
EyePoint, Inc. reported financial results for first quarter ended March 31, 2023.
“EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the first quarter ended March 31, 2023 and highlighted recent corporate developments.”
EyePoint, Inc. reported the fiscal year ended December 31, 2022 results: revenue $41.4 million.
“For the full year ended December 31, 2022, total net revenue was $41.4 million compared to $36.9 million for the full year ended December 31, 2021.”
EyePoint, Inc. reported the quarter ended December 31, 2022 results: revenue $10.5 million, net income $43.5 million, EPS ($1.16) per share.
“For the quarter ended December 31, 2022, total net revenue was $10.5 million compared to $11.5 million for the quarter ended December 31, 2021.”
EyePoint, Inc. entered into Lease with V.E. Properties IX, LLC valued at approximately $41 million (effective 2023-01-23).
“On January 23, 2023, EyePoint Pharmaceuticals, Inc. (the “Company”) and V.E. Properties IX, LLC (the “Landlord”) entered into a lease agreement (the “Lease”) relating to the lease by the Company of a to-be-constructed build-to-suit stand-alone commercial manufacturing facility”
EyePoint, Inc. reported full-year 2022 results: revenue exceed $39.5 million.
“Full-year 2022 net product revenue estimated to exceed $39.5 million versus $35.3 million in 2021”
Jay S. Duker changed role as President and Chief Operating Officer at EyePoint, Inc..
“Effective January 3, 2023 (the “Duker Start Date”), the Board of Directors (the “Board”) of the Company appointed Jay S. Duker, M.D., age 64, as the Company's President and Chief Operating Officer.”
EyePoint, Inc. shareholders approved Approval of 2016 Plan Amendment to the 2016 Long-Term Incentive Plan to increase the number of shares of Common Stock authorized for issuance thereunder by 2,000,000 shares.
“The Company’s stockholders approved the 2016 Plan Amendment to the 2016 Long-Term Incentive Plan to increase the number of shares of Common Stock authorized for issuance thereunder by 2,000,000 shares. The voting on this proposal is set forth below: Vote Type Vote Results For 29,012,113 Against 672,352 Abstain 61,027 Non Votes —”
EyePoint, Inc. reported third quarter ended September 30, 2022 results: revenue $10.0 million, net income $18.4 million, EPS ($.49) per share.
“For the third quarter ended September 30, 2022, total net revenue was $10.0 million compared to $9.1 million for the quarter ended September 30, 2021. Net product revenue for the third quarter was $9.7 million, compared to net product revenues for the third quarter ended September 30, 2021 of $8.6 million. Net revenue from royalties and collaborations for the third quarter ended September 30, 2022 totaled $0.3 million compared to $0.5 million in the corresponding period in 2021. Operating expenses for the third quarter ended September 30, 2022 totaled $28.4 million versus $24.4 million in the prior year period, primarily driven by investment in personnel across the organization, including non-cash stock compensation, and ongoing clinical trial and development costs for EYP-1901. Non-operating expense, net, totaled $0.02 million and net loss was $18.4 million, or ($.49) per share, compared to a net loss of $16.7 million, or ($0.58) per share, for the prior year period.”
Karen Zaderej was appointed as Director at EyePoint, Inc..
“increased the size of the Board to eight members and appointed Karen Zaderej to fill the vacancy on the Board, effective immediately.”
Michael C. Pine was appointed as Chief Corporate Development and Strategy Officer at EyePoint, Inc..
“On January 10, 2022 (the “ Start Date ”), EyePoint Pharmaceuticals, Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Michael C. Pine, age 46, as the Company’s Chief Corporate Development and Strategy Officer.”
Jay S. Duker was appointed as Chief Operating Officer at EyePoint, Inc..
“On November 1, 2021 (the “ COO Start Date ”), EyePoint Pharmaceuticals , Inc. (the “ Company ”) announced that the Board of Directors (the “ Board ”) of the Company appointed Jay S. Duker, M.D., age 63, as the Company's Chief Operating Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.